RATIONALLY DESIGNED SINGLE-ROUND INFECTIOUS VIRUS AND METHODS OF USE THEREOF

Provided are engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains. Also provided are compositions and methods for providing protective immune responses against influenza. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Also provided are methods for delivering co-stimulatory molecules, growth factors, adjuvants and/ or cytokines together with the non-replicating influenza viruses..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 27. Juli Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

KOK KIN HANG [VerfasserIn]
YUEN CHUN KIT [VerfasserIn]
YUEN KWOK YUNG [VerfasserIn]
WONG WAN MAN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-07-27, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08

Patentnummer:

WO2023138651

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017795516